Consolidated Statements Of Operations (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements Of Operations [Abstract]
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	1,025,628	3,088,192	4,788,055	3,879,666
Research and development (including stock-based compensation (Note 8))	28,360	51,956	98,494	100,957
Total operating expenses	1,053,988	3,140,148	4,886,549	3,980,623
Loss from operations	(1,053,988)	(3,140,148)	(4,886,549)	(3,980,623)
Other expense (income):
Interest expense	7,215	4,997	14,430	9,122
Interest income	(695)	(762)	(1,702)	(2,995)
Total Nonoperating Income/Expense	6,520	4,235	12,728	6,127
Net loss	(1,060,508)	(3,144,383)	(4,899,277)	(3,986,750)
Net loss attributable to the noncontrolling interest	1,171	1,323	14,274	3,093
Net loss attributable to Bion	(1,059,337)	(3,143,060)	(4,885,003)	(3,983,657)
Conversion inducement (Note 8)	(206,678)		(755,258)
Dividends on preferred stock	(1,875)	(136,637)	(151,425)	(254,774)
Net loss applicable to Bion's common stockholders	$ (1,267,890)	$ (3,279,697)	$ (5,791,686)	$ (4,238,431)
Net loss applicable to Bion's common stockholders per basic and diluted common share	$ (0.08)	$ (0.27)	$ (0.40)	$ (0.35)
Weighted-average number of common shares outstanding:
Basic and diluted:	15,818,467	12,178,602	14,634,645	12,129,578